Opinion
Video
Ronald D. Alvarez, MD, MBA, gives an analysis of the MIRASOL and DESTINY-PanTumor02 trials, including a comparison of study arms and discussion of HER2/neu targeting.
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Retifanlimab Becomes First FDA-Approved Frontline Treatment for Advanced Anal Cancer
Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups